Gilead presses HIV drug fraud in court, wins freeze of ‘kingpin’ assetsnews2022-04-19T18:33:57+00:00April 19th, 2022|Fierce Pharma|
Novavax, fashionably late to the COVID-19 vaccine party, could still reap $5B in 2022: analystnews2022-04-19T17:00:45+00:00April 19th, 2022|Fierce Pharma|
Gilead targets 400 jobs, assembles cell therapy manufacturing troika with FDA nod for Maryland sitenews2022-04-19T14:08:30+00:00April 19th, 2022|Fierce Pharma|
Johnson & Johnson, after weak quarter of vaccine sales, will no longer include it in guidancenews2022-04-19T14:03:18+00:00April 19th, 2022|Fierce Pharma|
SK advances Gates-backed COVID-19 antiviral spray toward clinicnews2022-04-19T13:31:16+00:00April 19th, 2022|Fierce Pharma|
Aquestive’s oral rival to EpiPen clears test on path to pivotal trialnews2022-04-19T13:27:13+00:00April 19th, 2022|Fierce Pharma|
Pfizer’s COVID-19 antiviral Paxlovid hits worldwide demand slump: reportnews2022-04-19T13:02:25+00:00April 19th, 2022|Fierce Pharma|
After rivals’ FDA rebuffs, GSK targets class-first oral approval in chronic kidney disease anemianews2022-04-19T13:02:16+00:00April 19th, 2022|Fierce Pharma|
Asahi Kasei scoops up CDMO Bionova, bolstering its antibody manufacturing capabilitiesnews2022-04-19T12:43:27+00:00April 19th, 2022|Fierce Pharma|
Galderma’s ‘Rosacea Space’ provides creative outlet for patients to share their experiences through art, poetry, photographynews2022-04-19T12:42:56+00:00April 19th, 2022|Fierce Pharma|
